Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Dependable recurring dividends from quality, high-yield stocks like these five are a recipe for passive income success.

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Bakery chain Greggs said on Thursday that it jumped past the £2bn sales mark in 2024, but reported a slowdown in like-for-like sales growth for the fourth quarter as weaker consumer confidence dented ...

To access these pages you must be a permanent member of University staff and registered on the UoB domain. Staff who are unable to access these pages or need additional access to student data should ...